RECENT NEWS

Researchers have developed a novel AI model that can analyse a routine whole histopathology image and simultaneously predict cancer subtype, specific genetic mutations, and survival outcomes across 32 different solid cancers rather than focusing on a single cancer type.

Researchers have applied a water freeze-drying (WFD) method to bacteria, enabling high-resolution SEM observation with a general-purpose laboratory freeze-dryer.

Scientists have discovered two new mechanisms for how a well-established antibiotic works, paving the way for potential development of new antibiotic treatment.

The world-first trial of a fridge-free tetanus-diphtheria vaccine has produced encouraging results that could improve access worldwide to crucial treatments, while reducing carbon emissions.

The UK Health Security Agency (UKHSA) has published new data which show around 50% fewer infants under six months being admitted to intensive care with RSV disease in England.

New research at Aston University has shown that a variety of compounds is responsible for the antimicrobial action of mānuka honey, not just the sugar content and methylglyoxal (MGO) alone, as previously thought.

Over 100,000 people in England have accessed potentially life-saving treatment for hepatitis C in the last 10 years as part of a groundbreaking NHS programme, new figures show.

OGT, a global provider of genomic research and diagnostic solutions, has announced its commitment to transition the full CytoCell fluorescence in situ hybridisation (FISH) probe portfolio from CE marking under the IVD Directive (IVDD) to the IVD Regulation (IVDR).

Leica Biosystems has announced multiple U.S. Food and Drug Administration (FDA) 510(k) clearances that strengthen its connected clinical digital pathology portfolio, translating digital pathology innovation to clinical impact by accelerating workflows and patient care.

The landmark Greenheys development at Manchester Science Park has been completed, offering 131,000 square foot of specialist laboratory and write-up space for the next generation of life sciences and tech innovation businesses.

SOPHiA GENETICS has announced a new global collaboration to develop, validate, and deploy companion diagnostics supporting precision oncology therapies with AstraZeneca.

The date and venue for next year's British Society for Microbial Technology (BSMT) Annual Microbiology Conference are now confirmed as Thursday 13 May 2027 at the Royal Air Force Museum in Hendon, North London.

A new report from The Royal College of Pathologists (RCPath) highlights serious forensic pathology workforce issues. Forensic Pathology Workforce 2026 shows how the mixed model of service delivery and employment models across the UK contributes to geographic inequity in vacancies and restricted training opportunities.

Proscia has received a new 510(k) clearance from the US Food and Drug Administration (FDA) for Concentriq AP-Dx. The clearance includes compatibility with the Leica Aperio GT 450 DX slide scanner, cloud deployment, and a Predetermined Change Control Plan (PCCP).

The NHS is to invite half a million men who have had or are living with prostate cancer to join a major research programme to improve early detection and treatment of the condition.

The Institute of Biomedical Science (IBMS) has published a new positioning paper calling for the controlled, independently evaluated implementation of AI-assisted digital cytology within NHS cervical screening programmes.

Tens of thousands of young people have received the first of a life-saving double dose of the meningitis B vaccine within just two weeks of the NHS launching its biggest ever catch-up campaign for the virus.

The Medical Research Council (MRC) has invested £50 million into the study of mitochondrial diseases to improve treatments.

POCT Innovators’ next Power to Disrupt one-day event takes place in Oxford on Monday 16 November, and booking is open now, with free places on offer to NHS workers.

A pioneering pathology technology developed by the National Pathology Imaging Co‑operative (NPIC) is set for international deployment after securing a commercial agreement with precision cancer diagnostics firm Epredia.